Development of a clinical-scale method for generation of dendritic cells from PBMC for use in cancer immunotherapy
Authors:
- 1 January 2001
- journal article
- Published by Elsevier in Cytotherapy
- Vol. 3 (1) , 19-29
Abstract
There is growing interest in the use of dendritic cells (DCs) for treatment of malignancy and infectious disease. Our goal was to develop a clinicalscale method to prepare autologous DCs for cancer clinical trials. PBMC were collected from normal donors or cancer patients by automated leukapheresis, purified by counterflow centrifugal elutriation and placed into culture in polystyrene flasks at 1 × 106 cells/mL for 5–7 days at 37°C, with 5% CO2, with IL-4 and GM-CSF. Conditions investigated included media formulation, supplementation with heatinactivated allogeneicAB serumor autologous plasma and time to harvest (Day 5 or Day 7). DCs were evaluated for morphology, quantitative yield, viability, phenotype and function, including mixed leukocyte response and recall response to tetanus toxoid and influenza virus. DCs with a typical immature phenotype (CD14-negative, CD1a-positive, mannose receptor-positive, CD80-positive, CD83-negative) were generated most consistently in RPMI 1640 supplemented with 10% allogeneic AB serum or 10% autologous plasma. Cell yield was higher at Day 5 than Day 7, without detectable differences in phenotype or function. In pediatric sarcoma patients, autologous DCs had enhanced function compared with monocytes from which they were generated. In this patient group, starting with 8.0 ± 3.7 × 108 fresh or cryopreserved autologous monocytes, DC yield was 2.1 ± 1.0 × 108 cells, or 29% of the starting monocyte number. In the optimized clinical-scale method, purified peripheral monocytes are cultured for 5 days in flasks at 1 × 106 cells/mL in RPMI 1640, 10% allogeneic AB serum or autologous plasma, IL-4 and GM-CSF. This method avoids the use of FBS and results in immature DCs suitable for clinical trials.Keywords
This publication has 17 references indexed in Scilit:
- Chemokine Up-Regulation and Activated T Cell Attraction by Maturing Dendritic CellsScience, 1999
- Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical applicationJournal of Immunological Methods, 1999
- Dendritic Cell Vaccines for Cancer ImmunotherapyAnnual Review of Medicine, 1999
- Comparative Analysis of Dendritic Cells Derived from Blood Monocytes or CD34+ Hematopoietic Progenitor CellsImmunobiology, 1998
- Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cellsNature Medicine, 1996
- Improved methods for the generation of dendritic cells from nonproliferating progenitors in human bloodJournal of Immunological Methods, 1996
- Generation of mature dendritic cells from human blood An improved method with special regard to clinical applicabilityJournal of Immunological Methods, 1996
- CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.Proceedings of the National Academy of Sciences, 1996
- Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha.Journal of Experimental Medicine, 1994
- Anaphylaxis to infusion of autologous bone marrow: An apparent reaction to self, mediated by IgE antibody to bovine serum albuminJournal of Allergy and Clinical Immunology, 1989